Descrizione del progetto
Biomarcatori predittivi della risposta all’immunoterapia nel linfoma a cellule B
I linfomi a cellule B sono tumori maligni ematologici derivanti dai linfociti B. Recentemente è emersa una promettente terapia basata su cellule T geneticamente modificate al fine di esprimere un recettore chimerico per antigene (CAR, chimeric antigen receptor) che ha come bersaglio il CD19 sui linfociti B, reindirizzando il sistema immunitario verso un’azione di attacco contro le cellule maligne. Finanziato dal programma di azioni Marie Skłodowska-Curie, il progetto BEAT B-cell Lymphoma si concentra sull’interazione tra le cellule CAR-T e quelle maligne all’interno del microambiente tumorale, con il principale obiettivo di scoprire nuovi biomarcatori per disporre di un feedback in tempo reale sulla risposta alla terapia CAR-T. Questi biomarcatori aiuteranno a prevedere gli esiti e a perfezionare la selezione dei pazienti per gli studi clinici, migliorando in ultima analisi l’efficacia della terapia CAR-T e i suoi effetti sui tessuti dei pazienti.
Obiettivo
"Project Title: BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in Tissue microenvironment
B-cell lymphomas, encompassing Follicular Lymphoma (FL) and Large B-cell Lymphoma (LBCL), pose significant health concerns. While the use of T-cells modified with a chimeric antigen receptor targeting CD19 (CART19) offers a potential breakthrough in treating these malignancies, it is imperative to unravel the intricate dynamics between the CART19 and the tumor B-cells within their unique tissue microenvironment (TME).
The ""BEAT B-cell Lymphoma"" initiative is poised to transform lymphoma therapeutic strategies. More than just advancing the status quo, this project is geared towards unveiling novel biomarkers that facilitate immediate feedback on therapeutic outcomes. These newfound markers will empower clinicians and patients with predictive tools for CART19 interventions and serve as cornerstones for redefining inclusion criteria in subsequent clinical trials. But the ambition of this endeavor goes beyond mere biomarker discovery. It promises in-depth revelations on how CART19 impacts actual patient-derived tissues, deepening our knowledge and inspiring fresh treatment avenues. The short term concrete vision? Fine-tuning CART19's performance and honing the initial patient selection process.
As a medical doctor with a specialization in hematopathology, I've offered numerous diagnoses of B-cell lymphomas, grounded in histological and molecular markers predominantly sourced from tumor B-cells. My foundational training as an immunologist has sharpened my curiosity, drawing my attention to the often underemphasized tissue microenvironment. My affinity for bioinformatics further equips me to navigate and interpret vast datasets efficiently. To ensure the success of this project and to further my journey towards becoming an independent researcher, I partnered with the renowned Alizadeh Lab at Stanford, USA and will later join the de Miranda lab in the Netherlands."
Parole chiave
Programma(i)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Invito a presentare proposte
(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global FellowshipsCoordinatore
2333 ZA Leiden
Paesi Bassi